Cancer biomarker

Genialis and Cancer Research Horizons Collaborate to Develop AI-Driven Patient Classifiers

Retrieved on: 
Monday, October 23, 2023
Research, Technology, Genetics, Software, Biotechnology, Health, Data Management, Science, Oncology, Artificial Intelligence, Society for Immunotherapy of Cancer, Cancer, ESMO, Biomarker, Therapy, RNA, Colorectal cancer, Conference, KRAS, Cancer Research UK, SITC, Cancer biomarker, Lung, Immunotherapy, Drug development, CRH, Algorithm, Society, Patient, Doctor of Philosophy, Pharmaceutical industry, Genial

Genialis , the RNA-biomarker company, today announced a new data-sharing collaboration with Cancer Research Horizons (CRH), the innovation arm of Cancer Research UK.

Key Points: 
  • Genialis , the RNA-biomarker company, today announced a new data-sharing collaboration with Cancer Research Horizons (CRH), the innovation arm of Cancer Research UK.
  • Under the terms of the collaboration, CRH will make anonymized and curated datasets with 'omics and clinical metadata available to Genialis to validate Genialis ResponderID™ technology and machine learning-derived patient classifiers.
  • Collaboration is key to expediting the development of clinically actionable biomarkers for better patient selection so that the right drug reaches the right patient at the right time.
  • “Cancer Research UK’s research network is generating huge amounts of detailed, highly curated data that can be used to support the development of tools and products that can benefit patients.

Harbinger Health Announces Data Demonstrating Its Ability to Detect Early-Stage Multi-Cancer at the AACC Annual Scientific Meeting 2023

Retrieved on: 
Wednesday, July 26, 2023
Abstract, DNA, Methylation, AACC, Cancer, Prognosis, Biomarker, Cancer biomarker, ASCO, American Society of Clinical Oncology, HIV disease progression rates, Reproducibility, Patient, Sequence, Annual general meeting, Biology, Neoplasm, American Association for Clinical Chemistry, Society, PCR, Harbinger, Disease, Pharmaceutical industry, Medical imaging, Nucleic acid thermodynamics

CAMBRIDGE, Mass., July 26, 2023 /PRNewswire/ -- Harbinger Health ("Harbinger," "the Company"), a biotechnology company pioneering the detection of early cancer, today announced data demonstrating the development and advancement of its biology and machine-learning-driven platform, HarbingerHx. The data were presented via three poster abstracts accepted at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo being held in Anaheim, Calif. on July 23-27, 2023.

Key Points: 
  • The data were presented via three poster abstracts accepted at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo being held in Anaheim, Calif. on July 23-27, 2023.
  • "Harbinger is pushing into new frontiers of cancer screening by pairing our proprietary insight into the biology of cancer's origins with our powerful technology platform," said Stephen M. Hahn, M.D., CEO of Harbinger Health.
  • "We aim to turn cancer into a disease that can be managed rather than feared.
  • The abstracts, which are now publicly available, follow Harbinger's recently announced results demonstrating high sensitivity for early-stage multi-cancer detection at the 2023 American Society of Clinical Oncology (ASCO)'s 2023 Annual Meeting.

Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform

Retrieved on: 
Friday, September 30, 2022
Apoptosis, Plasma, Cancer biomarker, FTIR, Brain, FDA, Liquid biopsy, Synthase, Cancer, U.S. Securities and Exchange Commission, Legislation, Knowledge, Company, OTCQB, Growth, Pressure, Lymphocyte, USD, Patient, Breast cancer, CEO, USPTO, Technology, Solution, TMB-2, TBIA, Notice, PCR, Method, Biotechnology, Research, Monocyte, Cell cycle, GLOBE, Amazon, Immune system, Patent, Neurodegeneration, Geology applications of Fourier transform infrared spectroscopy, Neuron, Alzheimer's disease, CAGR, Medical imaging, Pharmaceutical industry, Infrared, Pharma

The Notices of Allowance are for patent applications entitled 1) Infrared (IR) Spectroscopy System and 2) Infrared Analysis of Benign Tumors.

Key Points: 
  • The Notices of Allowance are for patent applications entitled 1) Infrared (IR) Spectroscopy System and 2) Infrared Analysis of Benign Tumors.
  • The Company has already received CE marks for its TBIA blood diagnostic test in breast cancer and colon cancer.
  • The global cancer diagnostics market is expected to experience growth at a CAGR of 8.4% over the forecast period 2022 to 2030.
  • Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease.

Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women

Retrieved on: 
Tuesday, August 23, 2022
Cancer biomarker, Cell cycle, Technology, TBIA, Vaccination, Monocyte, Neuron, Neurodegeneration, Research, Immunity, Legislation, Brain, Solution, Synthase, Pressure, Infection, Blood, Diagnosis, TMB-2, LDT, U.S. Securities and Exchange Commission, Method, Alzheimer's disease, GLOBE, PCR, Patient, Plasma, Monkeypox, Lymphocyte, Company, Immune system, Biotechnology, Cancer, Knowledge, Woman, Amazon, Apoptosis, OTCQB, Medical imaging, Pharmaceutical industry, Pharma

The first four enrollees in the case study series include three women and one man.

Key Points: 
  • The first four enrollees in the case study series include three women and one man.
  • The Company remains open to accepting additional patients into its MonkeyPox case study series.
  • The Company also intends to work closely with Amerimmune to measure effects of MonkeyPox on the immune system.
  • Patients who have had challenges being definitively diagnosed with MonkeyPox, especially women and children, can contact Provista for potential enrollment in the MonkeyPox case study series [email protected].

Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics

Retrieved on: 
Wednesday, August 10, 2022
Electric Bond and Share Company v. Securities and Exchange Commission, WP, CEO, GLOBE, Monkeypox, Brain, Knowledge, Research, Method, Patient, Monocyte, TBIA, US, Thermo Fisher Scientific, Immune system, Efficiency, Aerosol, Diagnosis, Neuron, Technology, Cell cycle, Lymphocyte, Biotechnology, Tecan, Neurodegeneration, Safety, U.S. Securities and Exchange Commission, Pressure, OTCQB, Physician, Amazon, Apoptosis, Wind, CA, CFX, Cancer, CDC, Synthase, COVID-19, COPD, Laboratory developed test, Solution, PCR, LDT, Eurosurveillance, Legislation, Population, RPP, Saliva, Plasma, Company, TMB-2, Alzheimer's disease, Reading, Automation, Intention, Cancer biomarker, Pharmaceutical industry, Medical device, Medical imaging, Pharma, Vizient, Inc.

New York, NY, and Tel Aviv, ISRAEL, Aug. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of its PCR-based Wound and Respiratory Pathogen panels.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Aug. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of its PCR-based Wound and Respiratory Pathogen panels.
  • With nine (9) liquid handling systems currently onsite at Provista from former Todos PCR testing lab clients, the Company expects Provista to soon be able to run up to 50,000 PCR tests per day.
  • The Company will continue to redeploy automation and equipment assets towards Provista as 3rd party lab testing contracts wind down.
  • Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel , and Provista's proprietary commercial-stage Videssa breast cancer blood test.

Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics

Retrieved on: 
Monday, June 13, 2022
Obstetrics, Caregiver, Precision medicine, Coronavirus, OTCQB, Company, COVID, Cancer biomarker, Research, Biotechnology, TBIA, Nausea, Knowledge, Cell cycle, Pressure, Plasma, Legislation, Monocyte, Breast cancer, Neuron, Cancer, Back pain, Fever, Solution, Incontinence, Synthase, U.S. Securities and Exchange Commission, Physician, Lethargy, Appetite, Brain, Method, GLOBE, Patient, Neurodegeneration, Risk, Technology, PCR, COVID-19, UTI, Immune system, TEL, Vomiting, Alzheimer's disease, Falls, Agitation, Lymphocyte, Urinary retention, Skin, Apoptosis, TMB-2, Pharmaceutical industry, Medical imaging

NEW YORK, NY and TEL AVIV, Israel, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of a 27-pathogen urinary tract infection (UTI) PCR precision medicine panel.

Key Points: 
  • NEW YORK, NY and TEL AVIV, Israel, June 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has completed validation of a 27-pathogen urinary tract infection (UTI) PCR precision medicine panel.
  • This e.coli pathogen overrepresentation leads to inappropriate therapy selection that results in poor outcomes for patients, including prolonged and worsening symptoms.
  • The second benefit of PCR testing vs. cell culture for UTI, is the rapid turnaround time for (24h-48h) vs. cell culture (3-7 days).
  • Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa breast cancer blood test.

Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET

Retrieved on: 
Friday, June 3, 2022
World Health Organization, Coronavirus, PET, OTCQB, Company, Death, Cancer biomarker, Biotechnology, Research, TBIA, Knowledge, Cell cycle, Pressure, Plasma, Legislation, Medicare, Monocyte, Neuron, Leipzig University, Disease, Cancer, World, Alzheimer's Association, Solution, Synthase, U.S. Securities and Exchange Commission, Brain, Method, GLOBE, Patient, Neurodegeneration, Technology, PCR, COVID-19, Immune system, Clinical trial, Association, Lymphocyte, Medicaid, Apoptosis, TMB-2, Medical device, Medical imaging, Pharmaceutical industry, Alzheimer's disease, Neuroscience

The Lymphocyte Proliferation Test (LymPro Test) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle.

Key Points: 
  • The Lymphocyte Proliferation Test (LymPro Test) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle.
  • LymPro is unique in the use of peripheral blood lymphocytes as surrogates for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
  • According to the Alzheimer's Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease.
  • Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease.

Todos Medical to Present at the Emerging Growth Conference

Retrieved on: 
Monday, April 25, 2022
Pressure, Monocyte, Biotechnology, U.S. Securities and Exchange Commission, COVID-19, Legislation, Research, Lymphocyte, Neuron, Cancer biomarker, Brain, GLOBE, PCR, Conference, Technology, Plasma, Company, Immune system, Cell cycle, Apoptosis, OTCQB, Solution, Method, TBIA, TMB-2, Coronavirus, Growth, Cancer, Neurodegeneration, Synthase, Knowledge, Alzheimer's disease, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, April 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical President and CEO Gerald Commissiong will present at the Emerging Growth Conference on April 27, 2022.

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, April 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical President and CEO Gerald Commissiong will present at the Emerging Growth Conference on April 27, 2022.
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests

Retrieved on: 
Tuesday, November 16, 2021
Industry, Vizient, Inc., Cancer biomarker, PCR, RPP, COVID-19, Cancer, Acquisition, Solution, Collection, Alzheimer's disease, Legislation, Safety, Plasma, CLIA, TBIA, Method, Technology, The New Client, Research, NLC, Biotechnology, Lymphocyte, GLOBE, Patient, Brain, Pressure, U.S. Securities and Exchange Commission, CEO, Neurodegeneration, Knowledge, Synthase, COVID, Todos, International joint venture, Apoptosis, OTCQB, TMB-2, Nursing, Neuron, Monocyte, Immune system, Company, Cell cycle, Pharmaceutical industry, Medical imaging

Provista will be providing COVID PCR, cPass Neutralizing Antibody and Respiratory Pathogen Panel (RPP) testing with local sample collection expected to yield less than 12-hour turnaround times.

Key Points: 
  • Provista will be providing COVID PCR, cPass Neutralizing Antibody and Respiratory Pathogen Panel (RPP) testing with local sample collection expected to yield less than 12-hour turnaround times.
  • The Company expects to initially add 2,000 COVID PCR tests monthly, and increase the overall production on a monthly basis.
  • Additionally, the New Client already services skilled nursing and long-term care facilities that are looking to add the cPass neutralizing antibody testing into their health & safety protocols for residents and staff.
  • As we move into the holiday traveling season with falling temperatures that lead people indoors, the PCR COVID, cPass, and RPP testing panel have become critically important tests.

Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers

Retrieved on: 
Tuesday, July 6, 2021
Oncology, Health, Medical devices, Genetics, Research, Science, Biotechnology, Branches of biology, Biology, Biomarkers, Life sciences, Biotechnology, Molecular biology, Laboratory techniques, Cancer biomarker, Polymerase chain reaction, Multiple sclerosis biomarkers, Digital polymerase chain reaction

This is the fourth issued patent for the technology, which identifies rare cancer biomarkers found in tissue, blood, and cerebrospinal fluid (CSF).

Key Points: 
  • This is the fourth issued patent for the technology, which identifies rare cancer biomarkers found in tissue, blood, and cerebrospinal fluid (CSF).
  • It can be used to enhance the performance and specificity of the PCR method, the most widely used amplification approach for research and clinical diagnostic applications.
  • Our strong and growing intellectual property portfolio enables Biocept to develop and commercialize our highly differentiated technologies and testing services.
  • This includes worldwide patent protection on its highly sensitive methods for detecting cancer biomarkers that are used by physicians for treatment decisions.